100 years of Mycobacterium bovis bacille Calmette-Guérin
Summary Mycobacterium bovis bacille Calmette-Guérin (BCG), an experimental vaccine
designed to protect cattle from bovine tuberculosis, was administered for the first time to a …
designed to protect cattle from bovine tuberculosis, was administered for the first time to a …
What have we learnt about BCG vaccination in the last 20 years?
HM Dockrell, SG Smith - Frontiers in immunology, 2017 - frontiersin.org
A number of new tuberculosis (TB) vaccines have been or are entering clinical trials, which
include genetically modified mycobacteria, mycobacterial antigens delivered by viral …
include genetically modified mycobacteria, mycobacterial antigens delivered by viral …
The BCG vaccine for COVID-19: first verdict and future directions
Despite of the rapid development of the vaccines against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses …
syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses …
[PDF][PDF] Galleria mellonella–intracellular bacteria pathogen infection models: the ins and outs
Galleria mellonella (greater wax moth) larvae are used widely as surrogate infectious
disease models, due to ease of use and the presence of an innate immune system …
disease models, due to ease of use and the presence of an innate immune system …
[HTML][HTML] Bacillus Calmette-Guérin (BCG) vaccine: a global assessment of demand and supply balance
T Cernuschi, S Malvolti, E Nickels, M Friede - Vaccine, 2018 - Elsevier
Over the past decade, several countries across all regions, income groups and procurement
methods have been unable to secure sufficient BCG vaccine supply. While the frequency of …
methods have been unable to secure sufficient BCG vaccine supply. While the frequency of …
[HTML][HTML] Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer's disease and Parkinson's disease
Bacillus Calmette–Guerin (BCG) is a live attenuated form of Mycobacterium bovis that was
developed 100 years ago as a vaccine against tuberculosis (TB) and has been used ever …
developed 100 years ago as a vaccine against tuberculosis (TB) and has been used ever …
BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny
Vaccines have been traditionally developed with the presumption that they exert identical
immunogenicity regardless of target population and that they provide protection solely …
immunogenicity regardless of target population and that they provide protection solely …
The enigmatic PE/PPE multigene family of mycobacteria and tuberculosis vaccination
MJ Brennan - Infection and immunity, 2017 - Am Soc Microbiol
The genome of Mycobacterium tuberculosis, the bacterium responsible for the disease
tuberculosis, contains an unusual family of abundant antigens (PE/PPEs). To date, certain …
tuberculosis, contains an unusual family of abundant antigens (PE/PPEs). To date, certain …
The Mycobacterium tuberculosis genome at 25 years: lessons and lingering questions
BN Koleske, WR Jacobs… - The Journal of clinical …, 2023 - Am Soc Clin Investig
First achieved in 1998 by Cole et al., the complete genome sequence of Mycobacterium
tuberculosis continues to provide an invaluable resource to understand tuberculosis (TB) …
tuberculosis continues to provide an invaluable resource to understand tuberculosis (TB) …
Tuberculosis susceptibility and vaccine protection are independently controlled by host genotype
The outcome of Mycobacterium tuberculosis infection and the immunological response to
the bacillus Calmette-Guerin (BCG) vaccine are highly variable in humans. Deciphering the …
the bacillus Calmette-Guerin (BCG) vaccine are highly variable in humans. Deciphering the …